Wall Street analyst price targets, ratings consensus & upside potential · Updated Feb 28, 2026
Last 12 months price action with 12-month analyst target path
As of March 2, 2026, FibroGen, Inc. (FGEN) has a Wall Street consensus price target of $28.00, based on estimates from 14 covering analysts. With the stock currently trading at $7.50, this represents a potential upside of +273.3%. The company has a market capitalization of $585M.
Analyst price targets range from a low of $28.00 to a high of $28.00, representing a 0% spread in expectations. The median target of $28.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Hold, with 5 analysts rating the stock as a Buy or Strong Buy,7 rating it Hold, and 2 rating it Sell or Strong Sell. The mixed ratings reflect uncertainty about near-term direction.
From a valuation perspective, FGEN trades at a trailing P/E of -15.6x. Analysts expect EPS to grow -122.4% over the next year.
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationSee how FGEN stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonThe consensus Wall Street price target for FGEN is $28, representing 273.3% upside from the current price of $7.5. With 14 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
FGEN has a consensus rating of "Hold" based on 14 Wall Street analysts. The rating breakdown is mixed, with 7 Hold ratings making up the largest segment. The consensus 12-month price target of $28 implies 273.3% upside from current levels.
FGEN's current price is $7.5 with a consensus target of $28 (273.3% implied move). Analyst estimates suggest the stock is undervalued at current levels.
The most bullish Wall Street analyst has a price target of $28 for FGEN, while the most conservative target is $28. The consensus of $28 represents the median expectation. These targets typically reflect 12-month expectations.
FGEN is moderately covered, with 14 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 5 have Buy ratings, 7 recommend Hold, and 2 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month FGEN stock forecast based on 14 Wall Street analysts shows a consensus price target of $28, with estimates ranging from $28 (bear case) to $28 (bull case). The median consensus rating is "Hold".
Wall Street analysts are very optimistic on FGEN, with a "Hold" consensus rating and $28 price target (273.3% upside). 5 of 14 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
FGEN analyst price targets range from $28 to $28, a 0% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $28 consensus represents the middle ground.